Myriad Historical Income Statement
| MYGN Stock | USD 16.27 0.01 0.06% |
Historical analysis of Myriad Genetics income statement accounts such as Other Operating Expenses of 1.1 B can show how well Myriad Genetics performed in making a profits. Evaluating Myriad Genetics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Myriad Genetics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Myriad Genetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Myriad Genetics is a good buy for the upcoming year.
Myriad |
About Myriad Income Statement Analysis
Myriad Genetics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Myriad Genetics shareholders. The income statement also shows Myriad investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Myriad Genetics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Myriad Genetics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Myriad Genetics minus its cost of goods sold. It is profit before Myriad Genetics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Myriad Genetics. It is also known as Myriad Genetics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Myriad Genetics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Myriad Genetics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.At this time, Myriad Genetics' Depreciation And Amortization is very stable compared to the past year. As of the 1st of December 2024, Other Operating Expenses is likely to grow to about 1.1 B, while Total Revenue is likely to drop about 414.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 690.6M | 678.4M | 753.2M | 414.1M | Depreciation And Amortization | 62.8M | 55.9M | 61.9M | 65.0M |
Myriad Genetics income statement Correlations
Click cells to compare fundamentals
Myriad Genetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Myriad Genetics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 161.1K | 71.4M | 62.8M | 55.9M | 61.9M | 65.0M | |
| Total Revenue | 851.1M | 557M | 690.6M | 678.4M | 753.2M | 414.1M | |
| Gross Profit | 650.1M | 378.8M | 493M | 476.4M | 517M | 327.5M | |
| Other Operating Expenses | 842.4M | 831.5M | 879.3M | 802.1M | 1.0B | 1.1B | |
| Operating Income | 7.6M | (194.8M) | (48.7M) | (123.7M) | (257.4M) | (244.5M) | |
| Ebit | 85.9M | (194.8M) | (48.7M) | (123.7M) | (248M) | (235.6M) | |
| Research Development | 85.9M | 80.9M | 81.9M | 85.4M | 88.7M | 63.0M | |
| Ebitda | 86.1M | (123.4M) | 14.1M | (67.8M) | (186.1M) | (176.8M) | |
| Cost Of Revenue | 201M | 178.2M | 197.6M | 202M | 236.2M | 248.0M | |
| Total Operating Expenses | 641.4M | 653.3M | 681.7M | 600.1M | 774.4M | 813.1M | |
| Income Before Tax | 7.7M | (283.7M) | (57.1M) | (140.6M) | (262.2M) | (249.1M) | |
| Total Other Income Expense Net | 100K | (88.9M) | (8.4M) | (16.9M) | (4.8M) | (4.6M) | |
| Net Income | 4.6M | (223.7M) | (27.2M) | (112M) | (263.3M) | (250.1M) | |
| Income Tax Expense | (4.4M) | 59.9M | (29.9M) | (28.6M) | 1.1M | 1.0M |
Pair Trading with Myriad Genetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Myriad Genetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Myriad Genetics will appreciate offsetting losses from the drop in the long position's value.Moving against Myriad Stock
| 0.91 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.84 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.84 | GILD | Gilead Sciences | PairCorr |
| 0.77 | VTRS | Viatris | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Myriad Genetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Myriad Genetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Myriad Genetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Myriad Genetics to buy it.
The correlation of Myriad Genetics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Myriad Genetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Myriad Genetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Myriad Genetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.